Ovarian tumours Flashcards
More common in pre/post menopausal women?
Post-menopausal women
Ovarian cancer - Risk factors
Increasing age - over 50
Nulliparity
Delayed pregnancy
Family history of ovarian and breast cancer
Ovarian cancer - Genetics
BRCA 1 and 2
HNPCC (Lynch syndrome)
Ovarian cancer - clinical features
Gradual symtoms Pelvic mass Persistent bloating Early satiety Abdominal pain Ascites Pressure symptoms (esp in bladder) Change of bowel habit Weight loss Pleural effusion SOB
Ovarian cancer often presents non-gynaecological. True or false?
True
Ovarian cancer - name 2 tumour markers
CA125
Carcino-embryonic antigen (CEA)
Normal levels of CA125 excludes ovarian cancer - true or false?
False
CA125 is raised in ovarian cancer ONLY. True or false?
False
- can be raised in other benign conditions such as endometriosis
Ovarian cancer - investigations
Tumour markers - CA125 - CEA Imaging - Transvaginal/abdo US - CT
Ovarian cancer - investigations - US findings
Complex mass with SOLID and CYSTIC area Multi-loculated Thick separations Associated ascites Bilateral disease
Ovarian cancer - investigations - what is the role of CT
Assess disease outwith the ovary
Screening is performed routinely for ovarian cancer. True or false?
False
Ovarian cancer - staging
FIGO stage
4 stages
Ovarian cancer - stage I
Confined to 1 or both ovaries
IA - cancer in one ovary
IB - cancer in both ovaries
IC - cancer in ovary and on the surface of one ovary
Ovarian cancer - stage II
Spread to other local pelvic organs e.g. uterus, fallopian tubes
Ovarian cancer - stage III
Spread beyond the pelvis within the abdomen
Ovarian cancer - stage IV
Spread into other organs e.g. liver, lungs
Ovarian cancer - management of treatable disease
Surgery
- bilateral salpino oophrectomy
Ovarian cancer - management of advanced disease
Surgery + Chemotherapy
What is the first line chemotherapy treatment of epithelial ovarian cancer?
Platinum agent
- carboplatin
- paclitaxel
Management of relapsed ovarian cancer in a platinum sensitive patient
Platinum based combination with paclitaxel, PLDH or gemcitabine
Management of relapsed ovarian cancer in a platinum resistant patient
Hormonal therapy
The OCP is protective against ovarian cancer. True or false?
True